2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 915

Increased Risk of Myocardial Infarction in Dermatomyositis and Polymyositis: A General Population-Based Cohort Study
Abstract Number: 2761

Increased Risk of Parenchymal Neurological Involvement in Behcet’s Syndrome Patients with Panuveitis
Abstract Number: 2466

Increased Risk of Rheumatoid Arthritis (RA) Among Shared Epitope-Negative (SE-) Mothers with Shared Epitope-Positive (SE+) Children
Abstract Number: 170

Increased Risk of Skin Reactions with Gout Medications: An Analysis of VA Databases
Abstract Number: 354

Increased Vascular Wall Inflammation in Patients with Active Rheumatoid Arthritis As Measured By an 18F-FDG-PET/CT Scan
Abstract Number: 488

Increases in Serum Cholesterol with Baricitinib Treatment Are Associated with Favorable Changes in Apolipoprotein Content and with Improvement in DAS28-CRP in Patients with Rheumatoid Arthritis
Abstract Number: 1932

Increasing Access to Inflammatory Arthritis Education in Rural and Remote Communities Using Telemedicine
Abstract Number: 436

Increasing Cartilage Turnover in Smokers Developing Rheumatoid Arthritis Is Associated with High Disease Activity in Early Disease
Abstract Number: 199

Increasing Complexity of Patients Undergoing Primary Total Hip Arthroplasty in the U.S
Abstract Number: 1154

Increasing Discrepancies Between Physician Assessment of Disease Activity and Patient Global Health in Germany Between 2000 and 2012
Abstract Number: 227

Increasing Fat-Mass May Reverse Bone Loss As Detected By DXA Scan
Abstract Number: 2318

Increasing Rates of Remission in Juvenile Idiopathic Arthritis through a Quality Improvement Learning Network – the Pediatric Rheumatology Care and Outcomes Improvement Network
Abstract Number: 1822

Increasing Synovitis and Bone Marrow Lesions Are Associated with Incident Joint Tenderness in Hand Osteoarthritis
Abstract Number: 2501

Indirect Comparison of Tocilizumab and Tofacitinib in Patients with Rheumatoid Arthritis
Abstract Number: 609

Induced Pluripotent Stem Cells (iPSCs) As a Tool for Unraveling the Role of Different Cell Types in the Disease Process of Spondyloarthritis Pathogenesis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].